Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
18.22
-0.78 (-4.11%)
At close: Oct 6, 2026, 4:00 PM EDT
18.50
+0.28 (1.54%)
Pre-market: Oct 7, 2026, 7:00 AM EDT
Viridian Therapeutics Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, Viridian Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $36.75. The average 1-year stock price forecast is 101.70% higher than the current stock price, while the lowest is $22 (+20.75%) and the highest is $50 (+174.42%).
Price Target: $36.75 (+101.70%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Viridian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 14 | 14 | 14 | 14 | 14 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 17 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Maintains $35 | Buy | Maintains | $35 | +92.10% | Oct 2, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $36 → $38 | Buy | Reiterates | $36 → $38 | +108.56% | Sep 22, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 1, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $39 → $40 | Buy | Maintains | $39 → $40 | +119.54% | Aug 20, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $40 | Buy | Maintains | $40 | +119.54% | Aug 13, 2026 |
Financial Forecast
Revenue This Year
30.04M
from 70.85M
Decreased by -57.59%
Revenue Next Year
233.98M
from 30.04M
Increased by 678.78%
EPS This Year
-3.93
from -3.32
EPS Next Year
-2.75
from -3.93
EPS and Forward PE are based on non-GAAP adjusted numbers.